{"nct_id":"NCT04915755","title":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-06","start_date":"2021-06-28","start_date_type":"ACTUAL","primary_completion_date":"2024-06-28","primary_completion_date_type":"ACTUAL","completion_date":"2025-12-31","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["GSK"]}